Nicas T I, Zeckel M L, Braun D K
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Trends Microbiol. 1997 Jun;5(6):240-9. doi: 10.1016/S0966-842X(97)01051-2.
The incidence of infections caused by resistant Gram-positive pathogens is increasing, while emergence of vancomycin resistance is reducing the number of therapeutic options. New agents are being rapidly evaluated as candidates to replace vancomycin; some of the most promising include semisynthetic glycopeptides, quinupristin-dalfopristin, oxazolidinones and everninomycins. Alternative strategies, including immunization and therapeutic vaccines, may also have a role.
